inflammatory conditions

Goal disorientation and lack of vision
Biotech

Celldex ends skin disease program after failing phase 2 test

A phase 2 study of Celldex’s barzolvolimab in a skin disease missed its primary endpoint, driving the biotech to end development in the indication.
Nick Paul Taylor Jul 22, 2026 6:00am
graphic image of different colored hands shaking

Merck bags $700M from Blackstone, spends $150M to regain asset

Nov 4, 2025 9:15am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Sitala seals $670M deal for Fosun immune disease drug

Aug 26, 2025 2:44pm
ducks in a row line up follow leader

Novartis lines up another potential indication for BTK inhibitor

Mar 9, 2024 12:00pm
fightmatch

MoonLake's IL-17 drug wins 'meet or beat' trial vs. competition

Jun 26, 2023 11:18am
Missed target failed trial trial failure

Aclaris stock sinks after phase 2a skin trial flop

Mar 6, 2023 11:29am